*IDORSIA AND VIATRIS UPDATE THEIR COLLABORATION FOR SELATOGREL AND CENERIMOD
*VIATRIS POTENTIAL REGULATORY AND SALES MILESTONES PAYMENTS TO IDORSIA REDUCED BY USD 250 MILLION
*IDORSIA'S CONTRIBUTION TO DEVELOPMENT COSTS REDUCED BY USD 100 MILLION
*AGREED ROYALTIES ON FUTURE SALES REMAIN UNCHANGED
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 26-FEB-202505:55:00.043 GMT